Abstract: An acetal- or ketal-containing disaccharide that is useful as a linker in antibody-drug conjugation. The disaccharide comprises a hexose linked to a N-acetylglucosamine oxazoline, and further comprises an acetal or ketal moiety bonded at a 4-position hydroxyl oxygen atom and a 6-position hydroxyl oxygen atom of the hexose. The acetal or ketal group can bear a variety of functional groups. Also provided are an antibody drug conjugate comprising an antibody linked to a therapeutic drug via the disaccharide. Also provided is a two-step method of making the acetal- or ketal-containing disaccharide.

Abstract: Provided herein are bifunctional lysosomal targeting degraders including a ligand configured to bind to transferrin receptor as a shuttle molecule for lysosome degradation, and a protein-binding moiety configured to bind a membrane or extracellular protein of interest, wherein the bifunctional lysosome targeting degraders can be recycled back out of cells and be catalytic. The bifunctional degraders find use, e.g., for selectively targeted degradation of membrane or extracellular proteins via the endosomal/lysosomal pathway. Also provided herein are compositions comprising the bifunctional degraders, as well as methods of using the bifunctional degraders.

Abstract: Provided herein are CARM1 PROTACs comprising a binding molecule of CARM1 with an optimized linker attached to an E3 ubiquitin ligase ligand that recruits the E3 ubiquitin ligase to CARM1. The PROTACs find use, e.g., for selectively targeted degradation of CARM1 protein in cancer cells. Also provided herein are compositions comprising the PROTACs, as well as methods of using the PROTACs.

Abstract: Provided herein are bifunctional lysosomal targeting degraders that comprise folate or a folate analog configured to bind to folate receptor as a shuttle molecule for lysosome degradation, and a protein binder configured to bind a membrane or extracellular protein of interest. The bifunctional degraders find use, e.g., for selectively targeted degradation of membrane and extracellular proteins via the endosomal/lysosomal pathway. Also provided herein are compositions comprising the bifunctional degraders, as well as methods of using the bifunctional degraders.

Abstract: A communication method and apparatus are provided. The method includes: A first device initiates, to a second device, a request for starting data transmission from the first device to the second device; the second device performs an acknowledgment reply to the request; and the first device may transmit data to the second device when the first device does not send an acknowledgment response for the acknowledgment reply to the second device. According to this application, unidirectional data transmission can be independently controlled, and data transmission efficiency can be improved.

Abstract: An address conflict detection method and apparatus are provided. The method includes: A first node sends a first message, where the first message includes a target network address field, an address type field, and a target system identifier field, the target network address field indicates a first network address, the address type field indicates a first address type corresponding to the first network address, the first address type is one of a plurality of address types, and the target system identifier field indicates identification information of a node for which the first network address is configured. The first node receives a second message from a second node, where the second message indicates whether an address conflict exists in the first network address.

Abstract: A packet sending and receiving method and an apparatus are provided. The method includes: a source node sends a first packet, where a packet header of the first packet carries a network address of a first intermediate node accessed by a destination node, and a routing header of the first packet carries a network address of the destination node; and after the node receives the first packet, if a network address of the node is not the network address of the first intermediate node, the node sends the first packet; or if a network address of the node is the network address of the first intermediate node, the node updates a destination address in the packet header of the first packet based on the network address of the destination node carried in the routing header, and sends an updated first packet.

Abstract: In one example communication method, a first node obtains logical channel information corresponding to a preset QoS parameter, where the logical channel information is used to establish a logical transmission channel between the first node and a second node, the second node is a neighboring node of the first node, and the logical transmission channel is used to provide QoS guarantee for a packet corresponding to the preset QoS parameter. The first node receives a first packet sent by the second node, where the first packet includes at least one of an SLNA of the second node or an L2ID of an interface of the second node. The first node performs communication at a network layer with the second node based on the logical channel information, the SLNA of the second node, and the L2ID of the interface of the second node.

Abstract: A method includes generating a first packet, where a first field in the first packet indicates that a type of the first packet is a first type or a second type, the first type corresponds to normal reliable broadcast, and the second type corresponds to improved reliable broadcast; or the first type corresponds to normal reliable multicast, and the second type corresponds to improved reliable multicast; and sending the first packet to a first device.

Abstract: Turbinmicin analogs of Formula I are provided. Compositions including Turbinmicin analogs of Formula I, such as pharmaceutical compositions including effective amounts of Turbinmicin analogs of Formula I for treating fungal infections such as Candida and Aspergillus, including drug-resistant strains thereof, are also disclosed. Methods of treating fungal infections with Turbinmicin analogs of Formula I and compositions thereof are disclosed.

Abstract: Provided herein are achiral cereblon (CRBN) ligands based on phenyl dihydrouracil that have optimal binding to CRBN without having chiral carbons. Also provided herein are the proteolysis targeting chimeras (PROTACs) comprising the CRBN ligands and a protein binder, pharmaceutical compositions containing the PROTACs, and methods of treating diseases using the PROTACs.

Abstract: The present invention disclosures a preparation method for a coated lithium ion sieve, the method comprises: S01: calcining manganese salt in an air atmosphere for 2 h˜10 h to form Mn2O3; S02: mixing Mn2O3 with lithium salt and grinding, reacting in a high-pressure reaction kettle at 100° C.˜200° C. for 36 h˜72 h to form a product of LiMnO2; wherein, the molar ratio of Mn2O3 and Li/Mn in the lithium salt is 1:1˜10:1; S03: adding LiMnO2 to a metal coating reagent and ultrasonic mixing for 2 h˜10 h, drying for 6 h˜24 h, and then calcining at 400° C.˜600° C. for 2 h˜10 h to form an oxide-coated Li1.6Mn1.6O4 lithium ion adsorbent; Wherein, the molar ratio of the metal coating reagent to LiMnO2 is 0.01:1˜0.08:1; S04: performing an acid treatment to the oxide-coated Li1.6Mn1.6O4 lithium-ion adsorbent to form an acidified product, washing the acidified product and drying to form the coated lithium-ion sieve.

Abstract: Histone deacetylase (“HDAC”)-selective inhibitors covalently bonded to a linker covalently bonded to an E3 ubiquitin ligase ligand, and salts thereof; pharmaceutical compositions containing them; methods of using the composition to inhibit neoplastic cell growth in mammals, including humans.

Abstract: An optical apparatus and a near-eye display device are provided. The optical apparatus includes a light source, an angle selection unit, a light conversion unit, a first polarization unit, a second polarization unit, and a lens. The first polarization unit is disposed on a light-emitting side of the light source; a first surface of the first polarization unit faces a light-emitting surface of the light source; the angle selection unit is disposed opposite the first polarization unit; the light conversion unit is disposed on a side, away from the first polarization unit, of the angle selection unit; the second polarization unit is disposed opposite the angle selection unit; and the lens is disposed opposite the light conversion unit.

Abstract: Disclosed are a short-distance optical amplification module, method and system. The module comprises a reflective type polarizing plate, a first phase delay plate, an imaging lens, a second phase delay plate and an absorptive type polarizing plate, arranged successively. The reflective type polarizing plate is arranged on a transmission path of an optical image. The first phase delay plate is arranged on the transmission path of the optical image passing through the reflective delay plate. The imaging lens is arranged on the transmission path of the optical image. The second phase delay plate is configured for converting a polarization direction of the optical image from an elliptical or circular polarization direction to a second linear polarization direction. The absorptive type polarizing plate is arranged on one side of the second phase delay plate that faces away from the imaging lens.

Abstract: The present disclosure provides compounds according to Formula I and pharmaceutically acceptable salts thereof, as well as compositions including such compounds and a pharmaceutically acceptable carrier or excipient. Further provided are methods of inactivating SIRT6 with compounds of Formula I as well as compounds of Formula III, W2—R2—Y—R3, as described herein. In addition, the present technology provides methods of treatment using such compounds to lower LDL levels, lower triglyceride levels, and/or increase glucose tolerance in a subject, and/or to inhibit proliferation of ovarian, colorectal, hepatocellular, non-small cell lung, glioblastoma, osteosarcoma, pancreatic, and skin cancer cells, and/or inhibit liver and/or kidney fibrosis, and/or promote corneal epithelial wound healing.

Abstract: An optical system and a near-eye display device are provided. The optical system includes a light-emitting source, a light conversion unit, and a first reflection unit. The light conversion unit is on a light exit side of the light-emitting source, and a first surface of the light conversion unit faces a light exit surface of the light-emitting source. The first reflection unit is on a side of the light conversion unit away from the light-emitting source, and a first angle is provided between a second surface of the first reflection unit and the first surface. A first light emitted by the light-emitting source is converted by the light conversion unit into a second light, and the second light is reflected by the first reflection unit.

Abstract: A self-assembled therapeutic dendron-micelle includes a first amphiphilic dendron-coil, a second amphiphilic dendron-coil, and optionally a third amphiphilic dendron-coil, and an encapsulated BRD4 ligand or BRD4 proteolysis targeting chimera. The first and optional third amphiphilic dendron-coils have a therapeutic peptide conjugated thereto. Also included are pharmaceutical compositions containing the dendron-micelles, methods of making the dendron-micelles, and therapeutic methods including administering the dendron-micelles to a subject in need thereof.

Abstract: Described are benzoimidazole indolyl methane compounds, pharmaceutical compositions containing them, and use of the compounds to inhibit PCSK9-mediated ailments.

Abstract: Compounds of the formula: pharmaceutical compositions containing the compounds, and methods of inhibiting neoplastic cell growth using the compounds and compositions.